![]() |
|
||||||||||||||
|
|||||||||||||||
![]() |
|||||||||||||||
Opportunities in |
FDA Grants Orphan Status to Clavis Pharma's Pancreatic Cancer DrugFriday, January 8 2010; Therapeutics DailyNorwegian firm Clavis Pharma ASA (OSL: CLAVIS) said today that its drug candidate Intravenous CP-4126 has been granted Orphan Drug Designation for the treatment of pancreatic cancer by the US Food and Drug Administration (FDA). more >> Sizzling market heats up biotech buyout feverDecember 8, 2009; Fierce BiotechBiotech buyouts are all the rage these days. Following fast on the heels of yesterday's news that. more >> Trellis, MedImmune ink antibody dealDecember 1, 2009; San Francisco Business TimesTrellis Bioscience Inc. sold a worldwide exclusive license that allows AstraZeneca plc’s MedImmune unit to develop and commercialize antibodies focused on respiratory syncytial virus. more >> More Biotechnology Updates >> |
||||||||||||||
Sitemap | Homepage | Who We Are | Why Biotech? | Why Biotech Investing? | Venture Capital | Private Equity | How to Invest Top Biotech Companies | Biotech Research | Biotech Investing Facts | About Biotech Investing | Clinical Trial Process | Contact Us © 2001-2010 InvestBio, Inc., a subsidiary of Diversified Private Equity Corporation (DPEC). All rights reserved. InvestBio is a registered trademark. All investments offered through DPEC Capital, Inc (Member FINRA/SIPC/SIFMA). |
|||||||||||||||